Security key
87975F104
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, no par value
- Total 13F shares
- 2,332,205
- Total 13F value
- $3,240,559
- Share change
- -474,330
- SEC-reported price per share
- $1.39
- Number of holders
- 31
- Value change
- -$616,944
- Number of buys
- 13
- Number of sells
- 30
- Shares outstanding
- 34,382,284
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q3 2025
Institutions
31
Top holders
10
TELO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Telomir Pharmaceuticals, Inc. SEC filings
Telomir Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87975F104
Recent filing periods:
Ownership snapshot
Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MIRA PHARMACEUTICALS, INC.
Disclosed value leader
MIRA PHARMACEUTICALS, INC.
Comparable rows
15/15
Latest evidence
29 Sep 2025
3/4/5
13F
Lead comparable stake: 10%
Showing 1-6 of 15 holder rows.
Quick read
MIRA PHARMACEUTICALS, INC. leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
MIRA PHARMACEUTICALS, INC.
10%
VANGUARD GROUP INC
3.3%
BlackRock, Inc.
1.1%
MILLENNIUM MANAGEMENT LLC
0.72%
GEODE CAPITAL MANAGEMENT, LLC
0.57%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. |
3/4/5
10%+ Owner
|
10%
|
$4,823,943
3,521,127 shares
|
— | 29 Sep 2025 |
| VANGUARD GROUP INC |
13F
Company
|
3.3%
|
$1,397,783
1,118,226 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
1.1%
|
$462,595
370,076 shares
|
— | 30 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.72%
|
$309,624
247,699 shares
|
— | 30 Jun 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.57%
|
$246,227
196,880 shares
|
— | 30 Jun 2025 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
0.47%
|
$200,743
160,594 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
2,332,205
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
42
Q3 2025 holders
31
Holder diff
-11
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend